Production (Stage)
ARS Pharmaceuticals, Inc.
SPRY
$14.98
$0.463.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -90.79% | 4,086.70% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -90.79% | 4,086.70% | |||
| Cost of Revenue | 3.96% | -14.18% | |||
| Gross Profit | -95.25% | 3,451.80% | |||
| SG&A Expenses | 15.81% | 84.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.64% | 65.37% | |||
| Operating Income | -178.77% | 317.02% | |||
| Income Before Tax | -167.58% | 362.56% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -167.97% | 361.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -167.97% | 361.05% | |||
| EBIT | -178.77% | 317.02% | |||
| EBITDA | -178.13% | 317.36% | |||
| EPS Basic | -167.51% | 360.12% | |||
| Normalized Basic EPS | -173.24% | 353.57% | |||
| EPS Diluted | -182.31% | 313.34% | |||
| Normalized Diluted EPS | -189.66% | 307.14% | |||
| Average Basic Shares Outstanding | 0.68% | 0.38% | |||
| Average Diluted Shares Outstanding | -17.74% | 22.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||